Protocol No.: C1071032

A Phase 3, Open-Label Study of Elranatamab Monotherapy versus Elotuzumab, Pomalidomide, Dexamethasone (EPd) or Pomalidomide, Brotezomib, Dexamethasone 9PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed/Refractory Multiple Myeloma who Received Prior Anti-CD38 Directed Therapy
Principal Investigator
Safi, Salah Ud Din
Phase
III
Age Group
Adult
Applicable Disease Site
Multiple Myeloma
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Kathryn Oliverio, LPN
Research Specialist
Phone: +1 304-293-7374

View on ClinicalTrials.gov